Multiple sclerosis

Lancet

Volumn 359, Issue 9313, 2002, Pages 1221-1231

  Compston, Alastair ^a   Coles, Alasdair ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GLATIRAMER; GROWTH FACTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MACROPHAGE MIGRATION INHIBITION FACTOR; METALLOPROTEINASE INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYELIN; NATALIZUMAB; PACLITAXEL; PLACEBO; RECOMBINANT GAMMA INTERFERON; RILUZOLE; T LYMPHOCYTE RECEPTOR; TERIFLUNOMIDE;

ANATOMY; AUTOIMMUNE DISEASE; AXONAL INJURY; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONVALESCENCE; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GLIA; GLIOSIS; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; TISSUE REPAIR;

EID: 0037029424     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08220-X     Document Type: Conference Paper

References (81)

1. The cost of multiple sclerosis
2. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis
3. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
4. Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis
5. The natural history of multiple sclerosis: A geographically based study, 2: Predictive value of the early clinical course
6. The natural history of multiple sclerosis: A geographically based study, 1: Clinical course and disability
7. Relapses and progression of disability in multiple sclerosis
8. Vaccinations and the risk of relapse in multiple sclerosis
9. Hepatitis B vaccination and the risk of multiple sclerosis
10. Rate of pregnancy-related relapse in multiple sclerosis
11. The genetic epidemiology of multiple sclerosis
12. A meta-analysis of genome screens in multiple sclerosis
13. A whole genome screen for linkage disequilibirum in multiple sclerosis confirms disease associations with regions previously linked to susceptibility
14. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis
15. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response
16. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
17. Nitric oxide donors reversibly block axonal conduction: Demyelinated axons are especially susceptible
18. Changed distribution of sodium channels along demyelinated axons
19. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: A functional magnetic resonance imaging study
20. Electrically active axons degenerate when exposed to nitric oxide
21. Axonal transection in the lesions of multiple sclerosis
22. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis
23. Axonal loss in normal-appearing white matter in a patient with acute MS
24. Transcallosal bands: A sign of neuronal tract degeneration in early MS?
25. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions
26. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons
27. A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons
28. Beta-interferon and multiple sclerosis
29. Interferon-beta in multiple sclerosis: Altering the balance of interleukin-12 and interleukin-10?
30. Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells
31. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
32. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
33. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
34. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
35. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
36. Mechanisms of action of glatiramer acetate in multiple sclerosis
37. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
38. Overview of azathioprine treatment in multiple sclerosis
39. New treatments and azathioprine in multiple sclerosis
40. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria
41. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome
42. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis, 1: Clinical effects
43. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis
44. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
45. The 5-year risk of MS after optic neuritis: Experience of the optic neuritis treatment trial
46. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis
47. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
48. Inpatient rehabilitation in multiple sclerosis: Do the benefits carry over into the community?
49. The cause and management of bladder, sexual and bowel symptoms in multiple sclerosis
50. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis
51. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study
52. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: A consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation
53. Anergy induction by dimeric TCR ligands
54. T-cell vaccination in multiple sclerosis: Immunoregulatory mechanism and prospects for therapy
55. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
56. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
57. Clinical trials of a phase III trial of oral myelin in replacing-remitting multiple sclerosis
58. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS
59. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
60. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
61. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
62. Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomised controlled trial
63. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
64. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
65. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
66. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
67. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
68. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
69. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
70. Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination
71. The restoration of conduction by central demyelination
72. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis
73. Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis
74. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis
75. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord
76. Identification of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons
77. Continuing optic nerve atrophy following optic neuritis: A serial MRI study
78. Heterogeneity in multiple sclerosis
79. A comparison of the pathology of primary and secondary progressive multiple sclerosis
80. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation
81. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination